Overview

A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the safety and tolerability of Caelyx used for the treatment of metastatic breast cancer (MBC), focusing on infusion reaction and palmar-plantar erythrodysesthesia (PPE).

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Doxorubicin
Liposomal doxorubicin